Approval by the Medicines and Healthcare products Regulatory Agency (MHRA) of AGAMREE® in the United Kingdom follows marketing authorization for this medicine in the EU and U.S.
MHRA acknowledges safety benefits of AGAMREE with regards to preserving bone health and maintaining growth compared to standard of care corticosteroids
Launches of AGAMREE in Europe, with Germany taking the lead, are planned to start in Q1-2024
January 12, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that AGAMRE
GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments.
The acquisition provides GSK with access to Aiolos’ AIO-001, a potentially best-in-
January 08, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.
“At Merck, we continue to enhance our oncology pipeline through strategic acquisitions that complement our current portfolio and advance br
Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial
Jan. 04, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products, and Foresight Diagnostics (Foresight), the leader in the development of ultra-sensitive liquid biopsy circulating tumor DNA (ctDNA) detection today announced a strategic partnership
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management
Cellarity collaboration will build upon initial work and engage the company’s platform to develop a small molecule therapy in metabolic dysfunction-associated steatohepatitis (MASH)
First two research programmes signed under existing partnership between Novo Nordisk and Flagship Pioneering
Novo Nordisk will reimburse R&D costs and each company and Flagship’